First Circuit Nixes Birth-Defect Lawsuit Against GlaxoSmithKline over Zofran Labeling
- January 20, 2023
The First Circuit upheld summary judgment for GlaxoSmithKline (GSK) in multidistrict litigation involving hundreds of product liability claims alleging that the company failed to warn consumers its anti-nausea drug Zofran could potentially cause birth defects if taken during pregnancy.
ARTICLE TAGS
You must be logged in to access this content.